Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the current study is to evaluate whether treatment with high doses of simvastatin can reduce coagulation activation in patients with acute coronary syndromes and if ezetimibe in conjunction with simvastatin may affect blood clotting in a similar manner.

The investigators hypotheses are as follows:

1. Intensive lipid lowering treatment with simvastatin (40 mg/day) and simvastatin (40 mg/day) combined with ezetimibe (10 mg/day) initiated after acute coronary syndrome leads to attenuation of blood coagulation including reduced thrombin generation, thrombin-mediated coagulant reactions, and improved structure of plasma clots.

2. Anticoagulant effects of simvastatin are weaker than those observed during administration of simvastatin and ezetimibe.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jagiellonian University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Ezetimibe; Simvastatin

Criteria

Inclusion Criteria:

• Age < 75 years

• Acute coronary syndrome (symptom onset < 12 h)

Exclusion Criteria:

• Diabetes on insulin

• Anticoagulant therapy

• Renal insufficiency

• Liver injury

• Acute cardiovascular event within the previous 3 months